Inhibin B grades sperm production well — and does two other jobs badly.
The closest thing to a direct blood marker of Sertoli cell function. It does not predict sperm retrieval at micro-TESE, and it does not predict fertility recovery after testosterone.
The closest thing to a direct blood measurement of sperm production — and the marker most often asked to do two jobs it cannot do.
What it measures
Inhibin B is a two-chain protein made by the Sertoli cells, the nurse cells that surround developing sperm inside the seminiferous tubule. It travels to the pituitary and suppresses FSH. FSH, in turn, stimulates the Sertoli cell. The two hormones sit in a closed loop, which is why they move in opposite directions on a report.
The reason inhibin B is described as a direct marker in a way FSH is not: FSH is a pituitary output, and it reflects Sertoli cell function only through a feedback loop that a diseased pituitary, an obese man’s altered signalling, or an androgen can interrupt. Inhibin B comes out of the tubule itself. Germ cells are required for adult production, so the signal is not merely “Sertoli cells exist” but “Sertoli cells with germ cells around them are working.”
That is the theory, and it is sound. What follows is where it does and does not deliver.
The assay reality — read this before comparing two results
There is no internationally standardised inhibin B reference interval for adult men, and results are not interchangeable between assay generations. The Beckman Coulter Gen II assay reads about 57% higher than the older DSL assay, related by the regression Gen II = 1.57 × DSL + 11.29 pg/mL. Two currently marketed second-generation kits diverge at high values, with an intraclass correlation of 0.915.
Published adult male values, each tied to its context:
| Population | Value (pg/mL) |
|---|---|
| Normozoospermic men, derived within a cross-sectional study of 30,613 men | 87.4–299.9 |
| Danish general population, aged 20–35, two centres | median 209 and 186 — the difference between centres was statistically significant |
| Laboratory-quoted adult male range cited in a doping study | 100–400 |
One pre-analytical point that catches people out: inhibin B falls about 3% per hour between 09:00 and 17:00. A morning draw, on one assay, compared only against that assay’s interval. Note also that 1 ng/L and 1 pg/mL are the same number, so papers reporting either are directly comparable.
Evidence: Established that results are assay-specific and not comparable across platforms.
What it does well: grading sperm production
This is the use the evidence supports.
In 30,613 men, inhibin B correlated with total sperm count at r = 0.311 overall, 0.208 in normozoospermic men and 0.444 in azoospermic men — and on stepwise regression it had a closer relationship with total sperm count than either FSH or testosterone. Against testicular histology in 52 azoospermic men, inhibin B below 79 pg/mL had sensitivity 78% and specificity 80% for the presence of spermatozoa, essentially matching FSH above 10 mU/mL (82% and 80%).
The most quotable finding is a combination result. In 349 Danish men, when inhibin B was below 80 pg/mL and FSH was above 10 IU/L simultaneously, the predictive power for a sperm count below 20 million per mL was 100%. Read that precisely: it is a positive predictive value within a doubly-abnormal subgroup. It says that when both markers are clearly abnormal the finding is reliable. It says nothing about how many men with low counts are missed.
One outlier deserves flagging rather than repeating. A 2024 single-centre study of 80 men reported inhibin B correlating with sperm count at r = 0.94 and an inhibin B/FSH ratio achieving an area under the curve of 0.986 with 100% sensitivity. Those figures sit far above everything else in the literature — an r of 0.94 against 0.31 to 0.44 in a 30,613-man cohort — in a small cross-sectional sample likely enriched for extremes. We mention it because you may encounter it. We are not going to build a page on it.
Evidence: Moderate for grading spermatogenesis; the correlation is real and modest, and the doubly-abnormal combination is genuinely informative.
What it does not do, part one: predict sperm retrieval
This is the use inhibin B is most often asked for, and the literature is largely negative.
The current best evidence is a 2024 systematic review and meta-analysis of 34 studies and 6,981 men with non-obstructive azoospermia undergoing microdissection testicular sperm extraction. The mean positive retrieval rate was 45%.
| Hormone | Pooled odds ratio for successful retrieval |
|---|---|
| Inhibin B | 1.01 (95% CI 1.00–1.02) |
| FSH | 1.03 (95% CI 1.00–1.06) |
| AMH | 0.82 (95% CI 0.73–0.92) |
The authors state it plainly: no study classified inhibin B as a predictor of successful retrieval, and neither FSH nor inhibin B predicted it. Anti-Müllerian hormone was the only marker that did.
The earlier meta-analysis of diagnostic accuracy reached a compatible conclusion with numbers that are more useful for counselling: serum inhibin B for predicting the presence of sperm at extraction had sensitivity 0.65 (95% CI 0.56–0.74) and specificity 0.83 (0.64–0.93), and its conclusion was that inhibin B “cannot serve as a stand-alone marker.” Applied to a pre-test probability of 41%, a reassuring result moves a man to a 73% chance of finding sperm; a discouraging one moves him to 23%.
That second number is the most useful thing on this page. A 23% chance of finding sperm is not a basis for cancelling a micro-TESE. A man told his inhibin B is “too low to bother” is being given a number that still leaves roughly one chance in four.
The largest clean negative primary study makes the point without any nuance at all: in 185 men with non-obstructive azoospermia, sperm were recovered in 49.7%, mean inhibin B was 37.3 pg/mL in the successful group versus 44.9 in the unsuccessful group — numerically lower where sperm were found — and the area under the curve was 0.51, which is a coin toss. Adding FSH did not help.
Positive studies exist and we are not hiding them. They are smaller, single-centre, and inconsistent with the pooled result. Where a literature contains both, the systematic review is the higher tier.
Evidence: Strong (null result) for inhibin B as a predictor of sperm retrieval at micro-TESE.
What it does not do, part two: predict fertility recovery after testosterone
Exogenous testosterone suppresses inhibin B — but partially, and never to zero. This is a real and useful asymmetry: androgen-induced suppression leaves inhibin B detectable, whereas germ-cell destruction from irradiation drives it to undetectable. In 15 men using testosterone for bodybuilding, inhibin B was 76 versus 182 ng/L in matched controls, about 58% lower — while testosterone, LH and FSH did not differ between the groups. That last detail is the interesting part and the one genuinely suggestive signal for inhibin B as an exposure marker. It has not been replicated at scale.
For recovery, the evidence points elsewhere. In the best-characterised cohort — 41 current androgen users, 31 past users a median of 300 days after stopping, and 21 non-users — past users were indistinguishable from never-users apart from residual reduced testicular volume. Mean time to recovery was 7.3 months for AMH, 10.7 for LH and 14.1 for sperm output; FSH, inhibin B and inhibin took longer than any of those. The authors’ nominated recovery markers were AMH, LH and FSH. Inhibin B is conspicuously not on that list.
And in the definitive integrated analysis of individual data from 30 studies and 1,549 men — about 90% of all published data on hormonal male contraception — seven predictors of faster recovery were identified: older age, Asian origin, shorter treatment duration, shorter-acting preparations, higher baseline sperm concentration, faster suppression, and lower baseline LH. Baseline inhibin B is not among them. Median time to a sperm concentration of 20 million per mL was 3.4 months; 90% had recovered by 12 months and 100% by 24.
There is one prospective observation that supports the biological plausibility of the claim, and it should be presented fairly. In 56 men on weekly testosterone enanthate, inhibin B remained suppressed during early recovery in the men whose spermatogenesis was slow to resume — despite higher FSH concentrations — and normalised at 24 weeks when the inverse relationship with FSH was restored. That is a group-level observation with no cut-off, no area under the curve, no sensitivity or specificity and no replication located. It makes the idea plausible. It does not make it clinical.
In the one head-to-head competition for which marker reflects persisting testicular damage years after androgen cessation, inhibin B lost: INSL3, but not inhibin B or testosterone, was associated with testicular size in former users.
Evidence: Limited for any recovery-prediction use; Unsupported as a clinical predictor of whether fertility will return.
Where inhibin B genuinely earns a prognostic role
In hypogonadotropic hypogonadism — men whose testes never received a gonadotropin signal — the baseline predictors of successfully inducing spermatogenesis with gonadotropin therapy are prior spontaneous testicular development with a volume above 4 mL, an inhibin B above 60 pg/mL, and no history of cryptorchidism.
That is the legitimate use, and it is a different population from a man stopping testosterone. The two are frequently conflated in consumer-facing material, and the 60 pg/mL threshold has never been validated in men discontinuing exogenous androgen. Do not carry it across.
What the guidelines say
Three guidelines, three closed lists, and inhibin B is on none of them.
The Endocrine Society’s 2018 guideline does not include it. The AUA and ASRM male infertility guideline specifies FSH and testosterone as the initial hormonal evaluation; inhibin B is not among the named tests. The EAU specifies total testosterone, FSH and LH — and where it does name an emerging marker for predicting sperm retrieval, it names AMH, not inhibin B.
That convergence is consistent with the retrieval literature above rather than a coincidence of omission.
Related
FSH · LH · Testosterone and fertility · Total testosterone · The Lab Library
Questions patients ask
What the test can tell you
Inhibin B is a better test than FSH because it comes from the testis.
Better in principle, roughly equal in practice, and worse for the one question people most want answered.
What the evidence showsAgainst testicular histology in 52 azoospermic men, inhibin B below 79 pg/mL gave sensitivity 78% and specificity 80%; FSH above 10 mU/mL gave 82% and 80%. In a head-to-head of 51 azoospermic men and 31 controls, areas under the curve were FSH 0.716, inhibin B 0.610 and AMH 0.565, with none superior to the others — and on logistic regression none of them predicted the presence of sperm. In a 30,613-man cohort, inhibin B did have a closer relationship with total sperm count than FSH on stepwise regression.
What remains uncertainWhether inhibin B adds anything in men whose FSH is already clearly elevated. One study suggests it does (area under the curve 0.73 versus 0.55 in that subgroup); it has not been replicated.
Bottom lineFor grading sperm production, inhibin B and FSH are close substitutes, and the pair together is more informative than either alone.
Moderate
My inhibin B was 95 at one lab and 150 at another, so one of them is wrong.
Both may be right. There is no standardised assay.
What the evidence showsThe Beckman Coulter Gen II assay reads about 57% higher than the older DSL assay, related by Gen II = 1.57 × DSL + 11.29 pg/mL. Two current second-generation kits diverge at high values. There is no internationally standardised reference interval for adult men. Inhibin B also falls about 3% per hour through the working day.
What remains uncertainHow many laboratories now use which generation. That information is often not on the report.
Bottom lineSame laboratory, same assay, morning draw, or the comparison is meaningless.
Strong
Sperm retrieval
My inhibin B is low, so a surgical sperm retrieval would not find anything.
This claim is more complicated than it sounds, and acting on it can cost a man his only chance.
What the evidence showsIn a meta-analysis of 34 studies and 6,981 men, the pooled odds ratio for inhibin B predicting successful retrieval was 1.01 (95% CI 1.00–1.02) — no predictive value at all — and the authors reported that no included study classified it as a predictor. AMH was the only marker that predicted retrieval, at 0.82 (0.73–0.92). In the largest clean negative study, 185 men with non-obstructive azoospermia, inhibin B was numerically lower in the men in whom sperm were found, and the area under the curve was 0.51.
What remains uncertainWhether some subgroup exists in which inhibin B is informative. Several small positive studies exist and conflict with the pooled result.
Bottom lineFrom an earlier meta-analysis, a discouraging inhibin B moves a man from a 41% to a 23% chance of finding sperm. That is worse odds, not no odds. Nobody should cancel a retrieval on this number.
Strong (null result)
Testosterone and fertility recovery
My inhibin B is suppressed on testosterone, so my sperm production is permanently damaged.
Suppression is the expected effect of the drug, and it is characteristically partial.
What the evidence showsTestosterone and progestogen suppression of spermatogenesis produces a partial reduction of inhibin B that is "never completely suppressed" — in contrast to testicular irradiation, after which it becomes undetectable. In men using testosterone for bodybuilding, inhibin B was 76 versus 182 ng/L in controls, about 58% lower, while testosterone, LH and FSH were indistinguishable between the groups.
What remains uncertainWhether an undetectable inhibin B on testosterone carries a different meaning from a merely low one. The physiology suggests it should; no study has tested it.
Bottom lineA suppressed inhibin B on testosterone is pharmacology. It is not by itself evidence of permanent damage.
Strong
An inhibin B test will tell me whether my fertility will come back after I stop.
It will not, and the researchers who studied recovery most closely recommended different markers.
What the evidence showsIn a cohort of 41 current users, 31 past users and 21 non-users, past users were indistinguishable from never-users apart from residual testicular volume. Mean recovery took 7.3 months for AMH, 10.7 for LH and 14.1 for sperm output, while FSH, inhibin B and inhibin all took longer — and the authors nominated AMH, LH and FSH as the useful recovery markers. In the integrated analysis of 1,549 men across 30 studies, seven predictors of faster recovery were identified and baseline inhibin B was not one of them.
What remains uncertainOne prospective study of 56 men found inhibin B stayed suppressed in the men whose spermatogenesis was slow to resume, despite higher FSH — a genuine signal that inhibin B might carry information FSH does not. It has no cut-off, no accuracy statistics and no replication.
Bottom lineThe reassuring general fact matters more than the test: 90% of men in the pooled contraceptive data recovered a sperm concentration of 20 million per mL by twelve months, and 100% by twenty-four.
Limited
Inhibin B should be part of routine monitoring for men on testosterone.
No guideline includes it, and it is not clear what you would do with the result.
What the evidence showsThe Endocrine Society's 2018 guideline does not name it. The AUA and ASRM male infertility guideline specifies FSH and testosterone. The EAU specifies total testosterone, FSH and LH, and names AMH rather than inhibin B where it discusses predicting sperm retrieval.
What remains uncertainNothing about the guidelines. What is genuinely unstudied is whether serial inhibin B during therapy would change any decision.
Bottom lineIf fertility matters to a man, the decision to be made is about the drug, not about the marker — that conversation belongs at testosterone and fertility, before starting.
Unsupported as routine monitoring
Clomiphene or a post-cycle protocol will restore inhibin B.
In the only randomised evidence, clomiphene did not move it at all.
What the evidence showsIn a randomised, double-blind, placebo-controlled cross-over study of ten men, there were no significant changes in inhibin B or AMH after either treatment period, although testosterone and estradiol rose on clomiphene. The authors concluded that clomiphene influenced Leydig cell activity but not Sertoli cell function. In hypogonadotropic hypogonadism, hCG alone for three months did not raise inhibin B in six men, while 24 months of hCG plus FSH did raise it and induced spermatogenesis in four of six.
What remains uncertainA great deal. The clomiphene trial has ten men in a specific population. No study of enclomiphene reporting inhibin B in adult men was located, and no study of hCG given alongside testosterone replacement reporting inhibin B was located either.
Bottom lineThe claim that these agents restore Sertoli cell function is not supported by the evidence that exists — which is thin in every direction.
Limited
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.
